New drug trial offers hope for women with Tough-to-Treat gynecologic cancers
NCT ID NCT06769152
Summary
This study is testing an experimental drug called HLX43 for women with advanced cervical or ovarian cancer that has returned or spread after standard first treatments didn't work or caused severe side effects. The Phase 2 trial will enroll about 130 participants to find the right dose and see how well the drug controls the cancer and how safe it is. Patients will receive the drug through an IV infusion at different dose levels to determine the most effective and tolerable option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital
RECRUITINGJi'nan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.